Abstract
Transfusion-related acute lung injury (TRALI) has been the leading cause of transfusion-associated death for nearly a decade. Recent TRALI mitigation strategies focused on reduction of leukocyte antibodies in high volume plasma products appear to be successful in reducing TRALI events and deaths, but additional preventive measures are needed. Future possibilities include, screening of donors for neutrophil antibodies, processing of blood products to reduce or remove biologic response modifiers, and the more judicious use of blood. There are currently no specific TRALI therapies. The pathogenesis of TRALI and acute lung injury-acute respiratory distress syndrome (ALI-ARDS) is quite similar; both involving interactions of activated platelets, neutrophils, and pulmonary endothelium resulting in lung damage, capillary leak, and pulmonary edema. Greater understanding of these interactions and the key molecules involved will lead to development of potential new targets for therapy. In this review, future possible preventive measures to further reduce the occurrence of TRALI will be discussed, including TRALI caused by biologic response modifiers (BRMs), like bioactive lipids and sCD40L, which are not addressed by current preventive actions that only target leukocyte antibodies in high-volume plasma products. Insights already gained from studies of ALI-ARDS treatments will be summarized and discussed as possible therapeutic targets for treatment of patients experiencing TRALI.
Keywords: TRALI, treatment, prevention, leukocyte antibodies, neutrophils, platelets, acute lung injury, transfusion-associated death, high volume plasma products, bioactive lipids
Current Pharmaceutical Design
Title:Future Preventive and Therapeutic Targets for Transfusion-Related Acute Lung Injury
Volume: 18 Issue: 22
Author(s): Brian R. Curtis
Affiliation:
Keywords: TRALI, treatment, prevention, leukocyte antibodies, neutrophils, platelets, acute lung injury, transfusion-associated death, high volume plasma products, bioactive lipids
Abstract: Transfusion-related acute lung injury (TRALI) has been the leading cause of transfusion-associated death for nearly a decade. Recent TRALI mitigation strategies focused on reduction of leukocyte antibodies in high volume plasma products appear to be successful in reducing TRALI events and deaths, but additional preventive measures are needed. Future possibilities include, screening of donors for neutrophil antibodies, processing of blood products to reduce or remove biologic response modifiers, and the more judicious use of blood. There are currently no specific TRALI therapies. The pathogenesis of TRALI and acute lung injury-acute respiratory distress syndrome (ALI-ARDS) is quite similar; both involving interactions of activated platelets, neutrophils, and pulmonary endothelium resulting in lung damage, capillary leak, and pulmonary edema. Greater understanding of these interactions and the key molecules involved will lead to development of potential new targets for therapy. In this review, future possible preventive measures to further reduce the occurrence of TRALI will be discussed, including TRALI caused by biologic response modifiers (BRMs), like bioactive lipids and sCD40L, which are not addressed by current preventive actions that only target leukocyte antibodies in high-volume plasma products. Insights already gained from studies of ALI-ARDS treatments will be summarized and discussed as possible therapeutic targets for treatment of patients experiencing TRALI.
Export Options
About this article
Cite this article as:
R. Curtis Brian, Future Preventive and Therapeutic Targets for Transfusion-Related Acute Lung Injury, Current Pharmaceutical Design 2012; 18 (22) . https://dx.doi.org/10.2174/1381612811209023285
DOI https://dx.doi.org/10.2174/1381612811209023285 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Short, but Highly Concentrated, Direct Inhalations of Essential Oil Molecules Improve Poor Sleep Quality: A Natural History Controlled, Withingroup, Self-administration Field Pilot Study
Current Psychopharmacology TNF-α Inhibitors with Anti-Oxidative Stress Activity from Natural Products
Current Topics in Medicinal Chemistry Inodilators in the Management of Low Cardiac Output Syndrome After Pediatric Cardiac Surgery
Current Vascular Pharmacology Exploring and Prioritization of Mobile-Based Self-Management Strategies for HIV Care
Infectious Disorders - Drug Targets Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review of SIRTUIN Activators as Potential Immunomodulators and their Influences on other Dysfunctions
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacology, Efficacy and Safety of Felodipine with a Focus on Hypertension and Angina Pectoris
Current Drug Safety Harnessing the Prevention Benefits of Antiretroviral Therapy to Address HIV and Tuberculosis
Current HIV Research Editorial: Ischemic Stroke Prevention
Current Vascular Pharmacology Editorial [ Has the Time Come for a New Definition of Microalbuminuria? ]
Current Vascular Pharmacology Phospholipase A2 Isoforms as Novel Targets for Prevention and Treatment of Inflammatory and Oncologic Diseases
Current Drug Targets Exercise as a platform for pharmacotherapy development in cardiac diseases
Current Pharmaceutical Design HIV: A Raft-Targeting Approach for Prevention and Therapy Using Plant-Derived Compounds (Review)
Current Drug Targets Antioxidants in Health, Disease and Aging
CNS & Neurological Disorders - Drug Targets Mycobacterial DNA Replication as a Target for Antituberculosis Drug Discovery
Current Topics in Medicinal Chemistry Vitamin D Intake and Obesity in Occupational Asthma Patients and the Need for Supplementation
Endocrine, Metabolic & Immune Disorders - Drug Targets The Crosstalk Between miRNA and Mammalian Circadian Clock
Current Medicinal Chemistry The Role of Novel Biomarkers of Cardiovascular Disease in Chronic Kidney Disease: Focus on Adiponectin and Leptin
Current Cardiology Reviews A Novel and Significant Method for Antioxidant Activity Utilizing Microtitre-plate (Resazurin Reducing Power Assay)
Current Chemical Biology Stress Hormone-Mediated DNA Damage Response -- Implications for Cellular Senescence and Tumour Progression
Current Drug Targets Vascular Lesion Thickness in the Lenticulostriate Artery Region Serves as a Biomarker for Early Neurological Deterioration
Current Neurovascular Research